FDA slaps hold on imetelstat studies; Geron whipped

Investors acted swiftly on 12 March driving shares of Geron down as low as 68.4% after it revealed the FDA had slapped a full clinical hold on the company's Phase II program for its experimental telomerase inhibitor imetelstat (GRN163L) over potential liver injury concerns.